Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348785 | 0.84 | SMN1; SMN2 (0.41) | HSD11B1SMN1; SMN2MITFCYP2B6KMT2A | |
| SCHEMBL2697747 | 0.83 | CYP2B6 (0.53) | SMN1; SMN2MITFCYP2B6KMT2AALDH1A1 | |
| SCHEMBL12581558 | 0.80 | TSHR (0.38) | SMN1; SMN2MITFKMT2ANPC1RAB9A | |
| SCHEMBL20476032 | 0.79 | KMT2A (0.39) | SMN1; SMN2MITFCYP2B6KMT2APOLB | |
| SCHEMBL2695770 | 0.78 | CYP2B6 (0.50) | SMN1; SMN2MITFCYP2B6KMT2AALDH1A1 | |
| SCHEMBL2297308 | 0.73 | CYP2B6 (0.62) | HSD11B1SMN1; SMN2CYP2B6NPC1RAB9A | |
| SCHEMBL12665881 | 0.72 | CYP2B6 (0.66) | HSD11B1SMN1; SMN2CYP2B6NPC1RAB9A | |
| SCHEMBL31583791 | 0.71 | CYP2B6 (0.42) | HSD11B1CYP2B6KMT2APOLBHPGD | |
| SCHEMBL122141 | 0.70 | BRD4 (0.41) | SMN1; SMN2MITFKMT2APOLBALDH1A1 | |
| SCHEMBL1625501 | 0.69 | MITF (0.40) | SMN1; SMN2MITFKMT2APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | HSD11B1 3156/4885SMN1; SMN2 1900/4885MITF 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.